Profile and potential of ixabepilone in the treatment of pancreatic cancer

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 923-930

  Smaglo, Brandon G ^a   Pishvaian, Michael J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Ixabepilone; Microtubules; Pancreatic cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; DASATINIB; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; IXABEPILONE; OXALIPLATIN; PACLITAXEL; SUNITINIB; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; TUBULIN MODULATOR;

ACNEIFORM RASH; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAXIMUM TOLERATED DOSE; MICROTUBULE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SOLID TUMOR; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; DRUG RESISTANCE; METASTASIS; PANCREATIC NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; TUBULIN MODULATORS;

EID: 84904357195     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S52964     Document Type: Review

References (32)

1. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1-7.
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165(1):68-72.
3. seer.cancer.gov [homepage on the Internet]. Bethesda, MD, USA: National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed July 9, 2013.
4. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31(3):443-481.
5. Goodin S. Novel cytotoxic agents: epothilones. Am J Health Sys Pharm. 2008;65(10):s10-s15.
6. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18(4):259-296.
7. Abu-Khalaf MM, Harris LN. Antimicrotubule agents. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA, USA: Lippincott, Williams and Wilkins; 2011.
8. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res. 2008;14(22):7167-7172.
9. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18 Suppl 5:v9-v15.
10. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cells. Proc Natl Acad Sci U S A. 2000;97(6):2904-2909.
11. Bollag DM, McQueeney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325-2333.
12. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7(5):1429-1437.
13. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel. J Biol Chem. 1997;272(4):2534-2541.
14. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol. 2012;30(Suppl 34):LBA148.
15. Dakik HK, Moskovic DJ, Carlson PJ, et al. The use of GTX as a second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2012;69(2):425-430.
16. De Jesus-Acosta A, Oliver GR, Blackford A, et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69(2):415-424.
17. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist. 2008;13(12):1207-1223.
18. US Food and Drug Administration. FDA approves Ixempra for advanced breast cancer patients. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109015.htm. Accessed July 31, 2013.
19. Awada A, Piccart M, Jones SF, et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother Pharmacol. 2009;63(3):417-425.
20. Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone, an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol. 2008;61(5):751-758.
21. He AR, Kunz PL, Pishvaian MJ, et al. A phase I study of an oral formulation of ixabepilone in patients with advanced cancer. J Clin Oncol. 2010;28(Suppl 15):e13090.
22. Kunz PL, He AR, Colevas AD, et al. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest New Drugs. 2012;30(6):2364-2370.
23. Whitehead RP, McCoy S, Rivkin SE, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a southwest oncology group study. Invest New Drugs. 2006;24(6):515-520.
24. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1997;15(6):2414-2419.
25. Burris HA, Moore, MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
26. Faivre S, Delbaldo C, Boige V, et al. Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies. Eur J Cancer. 2008;44(5):674-682.
27. Plummer R, Woll P, Fyfe D, et al. A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies. Clin Cancer Res. 2008;14(24):8288-8294.
28. Kittaneh M, Montero AJ, Kovacs K. Phase I trial of weekly and every 3 weeks ixabepilone and sunitinib in advanced solid tumors. J Clin Oncol. 2011;29(Suppl 15):3081.
29. Herbolsheimer P, Kapoor R, Smith KL, et al. Phase I trial of dasatinib and ixabepilone in patients with solid tumors. Invest New Drugs. 2013;31(1):92-98.
30. Sprycel [package insert]. Princeton, NJ, USA: Bristol-Myers Squibb Company; 2013.
31. Rocha Lima CM, Lin EH, Kim GP, et al. A phase 2 trial of ixabepilone plus cetuximab in first line-treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2012;5(5):155-160.
32. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19): 1817-1825